PIK3CA Mutations in In situ and Invasive Breast Carcinomas
Authors:
- Maria VaradiMVMaria Varadi
- Daniel CarrascoDCDaniel Carrasco
- Hailun LiHLHailun Li
- Lauren LuongoLLLauren Luongo
- Hee Jung KimHKHee Jung Kim
- So Yeon ParkSPSo Yeon Park
- Eun Yoon ChoECEun Yoon Cho
- Gretchen LewisGLGretchen Lewis
- Sarah KehoeSKSarah Kehoe
- J. Dirk IglehartJIJ. Dirk Iglehart
- Deborah DillonDDDeborah Dillon
- 14 July 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (14) , 5674-5678
Abstract
The PIK3 signaling pathway has been identified as one of the most important and most frequently mutated pathways in breast cancer. Somatic mutations in the catalytic subunit of PIK3CA have been found in a significant fraction of breast carcinomas, and it has been proposed that mutant PIK3CA plays a role in tumor initiation. However, the majority of primary human tumors analyzed for genetic alterations in PIK3CA have been invasive breast carcinomas and the frequency of PIK3CA mutations in preinvasive lesions has not been explored. To investigate this, we sequenced exons 9 and 20 of PIK3CA in pure ductal carcinoma in situ (DCIS), DCIS adjacent to invasive carcinoma, and invasive ductal breast carcinomas. In a subset of cases, both in situ and invasive areas were analyzed from the same tumor. We found that the frequency of PIK3CA mutations was essentially the same (∼30%) in all three histologic groups. In some cases, in situ and invasive areas of the same tumor were discordant for PIK3CA status, and in two cases in which multiple invasive and adjacent in situ areas within the same tumor were analyzed independently, we detected intratumor heterogeneity for PIK3CA mutations. Our results suggest that mutation of PIK3CA is an early event in breast cancer that is more likely to play a role in breast tumor initiation than in invasive progression, although a potential role for exon 9 mutations in the progression of a subset of DCIS cases cannot be excluded. Cancer Res; 70(14); 5674–8. ©2010 AACR.Keywords
All Related Versions
This publication has 17 references indexed in Scilit:
- A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodesBMC Cancer, 2010
- Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?Clinical Cancer Research, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagusInternational Journal of Cancer, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Oncogenic PI3K and its role in cancerCurrent Opinion in Oncology, 2006
- PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomasOncogene, 2004
- Mutation of the PIK3CA Gene in Ovarian and Breast CancerCancer Research, 2004
- PI3-kinase and TOR: PIKTORing cell growthSeminars in Cell & Developmental Biology, 2004
- Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinomaThe Journal of Pathology, 2002